febuxostat has been researched along with perphenazine in 2 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (perphenazine) | Trials (perphenazine) | Recent Studies (post-2010) (perphenazine) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 1,666 | 243 | 128 |
| Protein | Taxonomy | febuxostat (IC50) | perphenazine (IC50) |
|---|---|---|---|
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 14.79 | |
| Aldehyde oxidase 1 | Mus musculus (house mouse) | 6.1 | |
| Retinal dehydrogenase 1 | Homo sapiens (human) | 0.5242 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.216 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0003 | |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | 1.4 | |
| Aldehyde oxidase | Homo sapiens (human) | 0.033 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 4.216 | |
| Aldehyde oxidase 1 | Macaca fascicularis (crab-eating macaque) | 3.6 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.216 | |
| Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | 0.74 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for febuxostat and perphenazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for febuxostat and perphenazine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |